Works by Singh-Kandah, Shahnaz

Results: 7

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma.
Published in:
Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.975643
By:
- Khan, Shaheer;
- Patel, Sapna P.;
- Shoushtari, Alexander N.;
- Ambrosini, Grazia;
- Cremers, Serge;
- Shing Lee;
- Franks, Lauren;
- Singh-Kandah, Shahnaz;
- Hernandez, Susana;
- Sender, Naomi;
- Vuolo, Kristina;
- Nesson, Alexandra;
- Mundi, Prabhjot;
- Izar, Benjamin;
- Schwartz, Gary K.;
- Carvajal, Richard D.
Publication type:
Article
Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy.
Published in:
Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.976837
By:
- Khan, Shaheer;
- Lutzky, Jose;
- Shoushtari, Alexander N.;
- Jeter, Joanne;
- Marr, Brian;
- Olencki, Thomas E.;
- Cebulla, Colleen M.;
- Abdel-Rahman, Mohamed;
- Harbour, J. William;
- Sender, Naomi;
- Nesson, Alexandra;
- Singh-Kandah, Shahnaz;
- Hernandez, Susana;
- King, Jeanelle;
- Katari, Manpreet S.;
- Dimapanat, Lyssa;
- Izard, Stephanie;
- Ambrosini, Grazia;
- Surriga, Oliver;
- Rai, Alex J.
Publication type:
Article
Cutaneous Toxicities With Amivantamab for Non--Small Cell Lung Cancer (NSCLC) With Exon 20 Insertion Mutation (ex20ins): A Practical Guide and Best Practices for Management.
Published in:
Journal of Oncology Navigation & Survivorship, 2023, v. 14, n. 11, p. 353
By:
- Singh-Kandah, Shahnaz;
- Kaiwen Wang;
- Xia, Karen;
- Johnson, Andy L.;
- D'Andrea, Denise;
- Dougherty, Lindsay
Publication type:
Article
ESTABLISHING A DIVERSITY, EQUITY AND INCLUSION INITIATIVE IN A CANCER CLINICAL TRIAL OFFICE AT AN ACADEMIC CENTER.
Published in:
Oncology Nursing Forum, 2022, v. 49, n. 2, p. E94, doi. 10.1188/22.ONF.E2
By:
- Singh-Kandah, Shahnaz;
- Bentlyewski, Edward;
- Brogan, Frances;
- Minhaz, Moury;
- Genfi, Yacha;
- Crawford, Gail
Publication type:
Article
Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.
Published in:
Clinical Journal of Oncology Nursing, 2024, v. 28, n. 6, p. 559, doi. 10.1188/24.CJON.559-566
By:
- Singh-Kandah, Shahnaz;
- Kaiwen Wang;
- Xia, Karen;
- Johnson, Andy Lain;
- D'Andrea, Denise M.;
- Shu, Catherine A.;
- Dougherty, Lindsay Bray;
- Gallitano, Stephanie M.
Publication type:
Article
Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.
Published in:
Clinical Journal of Oncology Nursing, 2024, v. 28, n. 5, p. 1
By:
- Singh-Kandah, Shahnaz;
- Kaiwen Wang;
- Xia, Karen;
- Johnson, Andy Lain;
- D'Andrea, Denise M.;
- Shu, Catherine A.;
- Dougherty, Lindsay Bray;
- Gallitano, Stephanie M.
Publication type:
Article
A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma.
Published in:
Cancers, 2021, v. 13, n. 21, p. 5504, doi. 10.3390/cancers13215504
By:
- Shoushtari, Alexander N.;
- Khan, Shaheer;
- Komatsubara, Kimberly;
- Feun, Lynn;
- Acquavella, Nicolas;
- Singh-Kandah, Shahnaz;
- Negri, Tiffany;
- Nesson, Alexandra;
- Abbate, Kelly;
- Cremers, Serge;
- Musi, Elgilda;
- Ambrosini, Grazia;
- Lee, Shing;
- Schwartz, Gary K.;
- Carvajal, Richard D.
Publication type:
Article

Works by Singh-Kandah, Shahnaz

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma.

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy.

Cutaneous Toxicities With Amivantamab for Non--Small Cell Lung Cancer (NSCLC) With Exon 20 Insertion Mutation (ex20ins): A Practical Guide and Best Practices for Management.

ESTABLISHING A DIVERSITY, EQUITY AND INCLUSION INITIATIVE IN A CANCER CLINICAL TRIAL OFFICE AT AN ACADEMIC CENTER.

Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.

Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.

A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma.